

SSG Working group meeting February 2-4, 2014, Malmö

Report from the Oncology subcommittee

EURO EWING: Treatment of relapsed Ewing's family tumors. SSG is a partner of the EURO EWING Consortium where the objective is to run international clinical trials to improve survival for Ewing sarcoma patients. SSG will participate in Work package 2: "rEECur-a randomized trial on second line chemotherapy", which is a multiarm, multistage randomized study in recurrent disease. The protocol will soon be finished and the process with the regulatory authorities in the participating countries will then start immediately. Which Scandinavian countries and centers to participate and national coordinators to take action have to be determined. KSH ("National Co-Sponsor Investigator" on behalf of SSG) will forward the protocol to the central persons in Sweden, Denmark and Norway. Sweden (by Cecilia Petersen) will contact colleagues in Finland. The trial is being conducted under the auspices of the Cancer Research UK Clinical Trials Unit, University of Birmingham, UK. rEECur is sponsored by the University of Birmingham. Some funding has been received from the European Community.

EURELOS: - is a collaboration with COSS and ISG, with the aim of collecting data of different treatment results for recurring osteosarcoma. From SSG Norway and Sweden have decided to participate, Denmark and Finland will consider participation as soon as they receive the protocol from KSH. Necessary applications will soon be completed for Sweden, Norway has started this registration study.

GCP –Good clinical Practice is an international ethical and scientific quality standard for designing, conducting, recording and reporting trials. J. Ceberg, Lund provided useful information from her experience with monitoring at various SSG centers. There is a huge challenge for each center to meet all demands!

MODUFOLIN: The Swedish company Isofol has developed an active metabolite to leucovorin (Modufolin), with a potential improvement for

the rescue after high dose Methotrexate in osteosarcoma. In a limited phase I/II trial, Lund is participating together with centers in Warsaw and Budapest. Other SSG centers, especially in Sweden where necessary approvals have been given, may participate if decided soon. Later on, there may be a larger randomized trial between standard leucovorin and Modufolin.

MYXOID LIPOSARCOMA: P. Åhman, Gothenburg demonstrated promising results with HSP 90 inhibitor (Alvespimycin) in myxoid liposarcoma cell lines and inoculated mice expressing RET and ERBB3 receptor tyrosine kinases. Phase I studies in other malignancies have been performed and limited toxicity observed. ME have taken contact with the firm producing the drug, BMS, and is waiting for their hopefully positive response regarding a possible trial in MLS, either sponsored by BMS or with support from them.

“SSG TREATMENT GUIDELINES FOR RADIATION THERAPY FOR SOFT TISSUE SARCOMA”: N. Jebsen, Bergen and J. Engellau, Lund has initiated a project of writing guidelines for SSG. Other sarcoma specialists will be asked to participate in the working group. The group will present a first version on the SSG plenary meeting in Stockholm, May 2015.

ESMO GUIDELINES: An updated version will be available in 2014, and we will alert the SSG members with an e-mail.

The 37th SSG Plenary meeting in Stockholm, May 20- 22, 2015:
Abstract deadline February 15th, 2015.

March 1, 2014 K. Sundby Hall, Oslo, M. Eriksson, Lund